News Sentiment

HURA sentiment intelligence

TuHURA Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.39 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-2.0% over one week, +3.0% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.0% Price reacting lower
Trend fit Trend active 3.0% over four weeks
Fair value -86.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 42
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Market source 9
PR Newswire 9
www.marketscreener.com 5
Stock Titan 4
TradingKey 4
simplywall.st 4
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 18
Regulatory and legal 5
Deals and strategy 2
Analyst action 2
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
PR Newswire Direct company coverage

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences announced it has filed an Investigational New Drug (IND) application with the FDA for its TBS-2025 VISTA inhibiting antibody to treat molecularly defined subsets of AML and other blood cancers. The company targets initiating a Phase 1b/2 study in the second hal

Tone
Positive 74/100
Event
Regulatory and legal
Published
15 Jun 2026 12:14
Source
PR Newswire
Stock Titan Direct company coverage

New antibody to test in specific leukemia mutations as TuHURA files with FDA

TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, to treat molecularly defined subsets of AML and other blood cancers. The company plans a combined Phase 1b/2 study, targeting initiation in the secon

Tone
Negative 38/100
Event
Regulatory and legal
Published
15 Jun 2026 05:46
Source
Stock Titan
Stock Titan Direct company coverage

TuHURA (NASDAQ: HURA) taps $1.7M from $50M revolving loan facility

TuHURA Biosciences (NASDAQ: HURA) has drawn $1.7 million from its $50 million revolving credit facility with Parkview Holdings One LLC. This initial draw, made on May 26, 2026, will be used for general corporate purposes, providing additional liquidity for operations and developm

Tone
Neutral 50/100
Event
Balance sheet
Published
29 May 2026 20:39
Source
Stock Titan